Canopus* (6919) Submits Phase 3 Clinical Trial Application in Australia for New Drug CBL-514 for Abdominal Fat Reduction
NQ Score
3/100
N1 Content Completeness
4
AI Summary (NQ-processed)
Taiwanese biopharmaceutical company Canopus* announced that on May 20, 2026, it completed the submission of its second multinational, pivotal Phase 3 clinical trial (CBL-0302) application to Australia's Human Research Ethics Committee (HREC). The trial for its new drug candidate, CBL-514 injection, aims to reduce abdominal subcutaneous fat and is planned to enroll approximately 320 subjects across the United States, Canada, and Australia.